Phase 2 N=33 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate — 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Penicillin and Metronidazole in Treatment of Peritonsillar Abscess
Peritonsillar Abscess
Primary: Number of Participants With Recurrence of Peritonsillar Abscess — 10; 10 Participants — p=0.05
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Early Phase 1 N=48 Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
Phase 3 N=571 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 — -0.27; -0.72; -0.81 percentage of HbA1c — p=<0.0001
Phase 2 N=12 Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Primary: Response to Therapy — 10; 2 Participants
Phase 4 N=48 Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
Phase 3 N=108 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With an Observer Rating of Successful Participant Self-administration — 100; 100 percentage of participants
Phase 2 N=41 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants
Phase 3 N=770 Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 — -0.7; -0.8; -0.3 percentage of HbA1c — p=< 0.0001
Phase 3 N=140 Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH
Dentin Hypersensitivity
Primary: Percent Change in Mean Score of Pain Response From Baseline on Schiff Cold Air Sensitivity Scale Using Air Blast Stimulus — 18; 45; 37; 15 percentage of change in mean…
Phase 3 N=301 Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Glabellar Frown Lines
Primary: Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo — 142; 0 Participants
Phase 2 N=21 A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 1; 1; 2 Participants
Phase 4 N=37 A Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine
Femoro Acetabular Impingement
Primary: Visual Analogue Scale — 2.4; 2.7 cm
Phase 2 N=426 A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
Psoriasis
Primary: Achieving Psoriasis Area and Severity Index (PASI) - 75 at the End of Week 24 — 39.7; 47.2; 44.3; 20.0 percentage of total participants